Mayo Clinic Laboratory and Pathology Research Roundup: May 7

By Kelley Luedke • May 7, 2018

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer before Diagnosis

It is unclear how long pancreatic ductal adenocarcinomas (PDACs) are present before diagnosis. Patients with PDAC usually develop hyperglycemia and diabetes before the tumor is identified. If early invasive PDACs are associated with hyperglycemia, the duration of hyperglycemia should associate with the time that they have had the tumor. Mayo Clinic researchers collected data on patients with PDACs from medical databases in Olmsted County, Minnesota, from 2000 through 2015 and from the Mayo Clinic's tumor registry, from January 1, 1976, through January 1, 2017. They compared glycemic profiles of patients with PDAC (cases) compared to patients without cancer. Researchers also analyzed temporal fasting blood glucose (FBG) profiles collected for 60 months before patients received a PDAC diagnosis,  FBG profiles of patients with resected PDAC stratified by tumor volume and grade, and temporal FBG profiles of patients with resected PDACs from whom long-term FBG data were available. The primary outcome was to estimate duration of presence of invasive PDAC before its diagnosis based on hyperglycemia, defined as significantly higher FBG levels in cases compared to controls. In a case-control study of patients with PDAC from two databases, researchers associated FBG level with time to PDAC diagnosis and tumor volume and grade. Patients are hyperglycemic for a mean period of 26 to 30 months before PDAC diagnosis; this information might be incorporated in strategies for early detection. The study was published in Gastroenterology.

Published to PubMed This Week

• • • • • A Comparison of Clinical and Molecular Characteristics of Patients with Systemic Mastocytosis with Chronic Myelomonocytic Leukemia to CMML Alone
          Leukemia
        • Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis
          JAMA Neurology
        • Effects of NGM282, an FGF19 Variant, on Colonic Transit and Bowel Function in Functional Constipation: A Randomized Phase 2 Trial
          American Journal of Gastroenterology
        • The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases
          Journal of the American Society of Nephrology
        • Proliferative Glomerulonephritis with Monoclonal Immunoglobulin G Deposits is Associated with High Rate of Early Recurrence in the Allograft
          Kidney International
        • Teaching Video NeuroImages: Acquired Focal Neuromyotonia in LGI-1 Autoimmunity
          Neurology
        • Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis
          Ophthalmology
        • Synthesis of Multi-Omic Data and Community Metabolic Models Reveals Insights into the Role of Hydrogen Sulfide in Colon Cancer
          Methods
        • Newborn Screening for Proximal Urea Cycle Disorders: Current Evidence Supporting Recommendations for Newborn Screening
          Molecular Genetics and Metabolism
        • Laboratory Testing for Monoclonal Gammopathies: Focus on Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
          Clinical Biochemistry

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.